HRP20121023T1 - Inhibitori za iap - Google Patents
Inhibitori za iap Download PDFInfo
- Publication number
- HRP20121023T1 HRP20121023T1 HRP20121023TT HRP20121023T HRP20121023T1 HR P20121023 T1 HRP20121023 T1 HR P20121023T1 HR P20121023T T HRP20121023T T HR P20121023TT HR P20121023 T HRP20121023 T HR P20121023T HR P20121023 T1 HRP20121023 T1 HR P20121023T1
- Authority
- HR
- Croatia
- Prior art keywords
- compounds
- formula
- inhibitors
- image
- phenyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 4
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- 230000001028 anti-proliverative effect Effects 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 102000029749 Microtubule Human genes 0.000 claims 3
- 108091022875 Microtubule Proteins 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 210000004688 microtubule Anatomy 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 229960004964 temozolomide Drugs 0.000 claims 2
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 1
- ZCHCHJQEWYIJDQ-UHFFFAOYSA-N 2-methyl-1,3-oxazole Chemical compound CC1=NC=CO1 ZCHCHJQEWYIJDQ-UHFFFAOYSA-N 0.000 claims 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 102100024025 Heparanase Human genes 0.000 claims 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 229940124761 MMP inhibitor Drugs 0.000 claims 1
- 101710181812 Methionine aminopeptidase Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 230000002280 anti-androgenic effect Effects 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 229940046836 anti-estrogen Drugs 0.000 claims 1
- 230000001833 anti-estrogenic effect Effects 0.000 claims 1
- 239000000051 antiandrogen Substances 0.000 claims 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims 1
- 239000002814 antineoplastic antimetabolite Substances 0.000 claims 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 229940046844 aromatase inhibitors Drugs 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000328 estrogen antagonist Substances 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 1
- 229960001442 gonadorelin Drugs 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims 1
- 108010037536 heparanase Proteins 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 229940124302 mTOR inhibitor Drugs 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 231100000590 oncogenic Toxicity 0.000 claims 1
- 230000002246 oncogenic effect Effects 0.000 claims 1
- 208000023983 oral cavity neoplasm Diseases 0.000 claims 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
- 150000002916 oxazoles Chemical class 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 150000003058 platinum compounds Chemical class 0.000 claims 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 239000003277 telomerase inhibitor Substances 0.000 claims 1
- 150000003918 triazines Chemical class 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 208000037964 urogenital cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (18)
1. Spojevi, naznačeni time, da imaju formulu (IV)
[image]
gdje U je:
[image]
i gdje
(a) R1 i R3 su metil ili etil;
R2 je H, metil, etil, klorometil, diklorometil ili trifluorometil;
R4 je C1-C4alkil; C3-C7 cikloalkil; C3-C7 cikloalkil-C1-C7alkil; fenil-C1-C7alkil ili aril, R5 je H;
U ima strukturu formule II gdje
X je N;
R6, R’6, R7 i R’7 su H; ili R6 je -C(O)-C1-C4alkil-fenil i R’6, R7 i R’7 su H;
n je 0, tako da oba (Ra)n i (Rb)n označavaju vezu;
Rc je H;
Rd je Ar1-D-Ar2, pri čemu su Ar1 i Ar2 supstituirani ili nesupstituirani fenil ili het:
i D je N(Rh), gdje Rh je H, Me, -CHO, -SO2, -C(O), -CHOH, -CF3 ili -SO2CH3;
ili gdje
(b) R1 i R3 su metil ili etil;
R2 je H, metil, etil, klorometil, diklorometil ili trifluorometil;
R4 je C1-C4alkil; C3-C7cikloalkil; C3-C7cikloalkil- C1-C7alkil; fenil-C1-C7alkil ili aril;
R5 je H;
U ima strukturu formule II gdje
X je N;
R6, R’6, R7 i R’7 su H;
n je 0, tako da oba (Ra)n i (Rb)n označavaju vezu;
Rc je H;
Rd je Ar1-D-Ar2, gdje su Ar1 i Ar2 supstituirani ili nesupstituirani fenil ili het;
i D je -O-;
ili gdje
(c) R1 i R3 su metil ili etil;
R2 je H, metil, etil, klorometil, diklorometil ili trifluorometil;
R4 je C1-C4alkil ili C3-C7cikloalkil;
R5 je H;
U ima strukturu formule II gdje
X je N;
R6, R’6, R7 i R’7 su H;
n je 0, tako da oba (Ra)n i (Rb)n označavaju vezu;
Rc je H;
Rd je Ar1-D-Ar2;
Ar1 i Ar2 su supstituirani ili nesupstituirani fenil ili het;
i D je C(O);
pri čemu je "het" 5-7-člani heterociklički prsten koji sadrži 1-4 heteroatoma odabrana od N, O i S, ili 8-12-člani kondenzirani sustav prstena uključujući najmanje jedan 5-7-člani heterociklički prsten koji sadrži 1, 2 ili 3 heteroatoma odabrana od N, O i S, gdje je spomenuti heterociklički prsten ili kondenzirani sustav prstena nesupstituiran ili supstituiran na atomu ugljika ili dušika;
ili njihove farmaceutski prihvatljive soli.
2. Spojevi formule (IV) prema zahtjevu 1, naznačeni time, da D je N(Rh), a R4 je metil, etil, butil, izopropil, t-butil, cikloheksil, -CH2-ciklopentil, -CH2-cikloheksil, -CH2-ciklopropil, fenil ili -CH2-fenil.
3. Spojevi formule (IV) prema zahtjevu 1 ili 2, naznačeni time, da D je N(Rh), a Ar1 i Ar2 su supstituiran ili nesupstituiran fenil ili het, gdje je spomenuti het supstituiran ili nesupstituiran triazin, pirimidin, piridin, oksazol, 2,4-difluorofenil, Cl-fenil ili fluorofenil.
4. Spojevi formule (IV) prema zahtjevu 1, naznačeni time, da D je -O- i R4 je metil, etil, butil, izopropil, t-butil, cikloheksil, -CH2-ciklopentil, -CH2-cikloheksil, -CH2-ciklopropil, fenil ili -CH2-fenil.
5. Spojevi formule (IV) prema zahtjevu 1 ili 4, naznačeni time, da D je -O-, a Ar1 i Ar2 su supstituiran ili nesupstituiran fenil ili het, gdje je spomenuti het supstituiran ili nesupstituiran pirimidin, piridin, oksazol ili 2-metiloksazol.
6. Spojevi formule (IV) prema zahtjevu 1, naznačeni time, da D je C(O), a R4 je izopropil, t-butil, ciklopentil ili cikloheksil.
7. Spojevi formule (IV) prema zahtjevu 1 ili 6, naznačeni time, da D je C(O), a Ar1 i Ar2 su supstituiran ili nesupstituiran fenil ili het, gdje je spomenuti het supstituiran ili nesupstituiran oksazol, tiazol ili oksadiazol.
8. Spojevi formule (IV) prema zahtjevu 1, naznačeni time, da su odabrani od sljedećih:
Primjer 6
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
i Primjer 195
[image]
ili njihove farmaceutski prihvatljive soli.
9. Farmaceutski sastav, naznačen time, da obuhvaća farmaceutski prihvatljiv nosač i terapeutski učinkovitu količinu spoja formule (IV) prema bilo kojem od zahtjeva 1 do 8.
10. Spojevi formule (IV) prema bilo kojem od zahtjeva 1 do 8, naznačeni time, da se upotrebljavaju u medicini.
11. Uporaba spoja formule (IV) prema bilo kojem od zahtjeva 1 do 8, naznačena time, da je za proizvodnju lijeka za liječenje proliferativne bolesti.
12. Uporaba prema zahtjevu 11, naznačena time, da proliferativna bolest je tumor.
13. Uporaba prema zahtjevu 11 ili 12, naznačena time, da je proliferativna bolest odabrana od sljedećih: rak dojke, urogenitalni rak, rak pluća, gastrointestinalni rak, epidermalni rak, melanom, rak jajnika, rak gušterače, neuroblastom, rak glave i/ili vrata, rak mjehura, renalni ili gastrički rak, rak mozga, tumor usta, plućni tumor, kolorektalni tumor, tumor prostate i multipli mijelom.
14. Kombinacija, naznačena time, da obuhvaća spoj formule (IV) prema bilo kojem od zahtjeva 1 do 8 i neko drugo antiproliferativno sredstvo.
15. Kombinacija prema zahtjevu 14, naznačena time, da je drugo antiproliferativno sredstvo odabrano od sljedećih: inhibitori aromataze; antiestrogeni, inhibitori topoizomeraze I; inhibitori topoizomeraze II; mikrotubulna aktivna sredstva; alkilacijska sredstva; inhibitori histonske deacetilaze; spojevi koji induciraju stanične diferencijacijske procese, inhibitori ciklooksigenaze; MMP-inhibitori; mTOR-inhibitori; antineoplastični antimetaboliti; platinski spojevi; spojevi koji ciljaju na aktivnost kinaze proteina ili lipida, na primjer da je smanjuju i drugi antiangiogenski spojevi; spojevi koji ciljaju na aktivnost fosfataze proteina ili lipida, na primjer da je smanjuju ili inhibiraju; gonadorelinski agonisti; antiandrogeni; inhibitori aminopeptidaze metionina; bisfosfonati; tvari koje modificiraju biološku reakciju; antiproliferativna protutijela; inhibitori heparanaze; inbitori onkogenskih Ras-izoforma; inhibitori telomeraze; inhibitori proteazoma; sredstva koja se koriste u liječenju hematoloških maligniteta; spojevi koji ciljaju na aktivnost Flt-3, na primjer da je smanjuju ili inhibiraju; Hsp90-inhibitori; temozolomid (TEMODAL®) i leukovorin.
16. Kombinacija prema zahtjevu 15, naznačena time, da drugo antiproliferativno sredstvo je mikrotubulno aktivno sredstvo.
17. Kombinacija prema zahtjevu 16, naznačena time, da mikrotubulno aktivno sredstvo je paklitaksel ili docetaksel.
18. Spojevi formule (IV) prema bilo kojem od zahtjeva 1 do 8, naznačeni time, da se upotrebljavaju za liječenje bilo koje indikacije opisane u bilo kojem od zahtjeva 11, 12 ili 13.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56018604P | 2004-04-07 | 2004-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20121023T1 true HRP20121023T1 (hr) | 2013-01-31 |
Family
ID=34962601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20121023TT HRP20121023T1 (hr) | 2004-04-07 | 2012-12-12 | Inhibitori za iap |
Country Status (32)
Country | Link |
---|---|
US (4) | US20080242658A1 (hr) |
EP (3) | EP2253614B1 (hr) |
JP (3) | JP4691549B2 (hr) |
KR (2) | KR20080083220A (hr) |
CN (1) | CN1964970B (hr) |
AR (1) | AR048927A1 (hr) |
AU (1) | AU2005231956B2 (hr) |
BR (1) | BRPI0509721A (hr) |
CA (1) | CA2560162C (hr) |
CY (1) | CY1113511T1 (hr) |
DK (1) | DK2253614T3 (hr) |
EC (1) | ECSP066893A (hr) |
ES (2) | ES2394441T3 (hr) |
HK (1) | HK1100930A1 (hr) |
HR (1) | HRP20121023T1 (hr) |
IL (1) | IL178104A (hr) |
MA (1) | MA28630B1 (hr) |
ME (1) | ME02125B (hr) |
MY (1) | MY165401A (hr) |
NO (1) | NO20065114L (hr) |
NZ (1) | NZ549925A (hr) |
PE (2) | PE20110102A1 (hr) |
PL (1) | PL2253614T3 (hr) |
PT (1) | PT2253614E (hr) |
RS (1) | RS52545B (hr) |
RU (1) | RU2425838C2 (hr) |
SG (1) | SG152225A1 (hr) |
SI (1) | SI2253614T1 (hr) |
TN (1) | TNSN06323A1 (hr) |
TW (1) | TWI417092B (hr) |
WO (1) | WO2005097791A1 (hr) |
ZA (1) | ZA200607696B (hr) |
Families Citing this family (140)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005228950B2 (en) | 2004-03-23 | 2012-02-02 | Genentech, Inc. | Azabicyclo-octane inhibitors of IAP |
AR048927A1 (es) * | 2004-04-07 | 2006-06-14 | Novartis Ag | Compuestos heterociclicos como inhibidores de proteinas de apoptosis (iap); composiciones farmaceuticas que los contienen y su uso en el tratamiento de una enfermedad proliferativa |
CA2570321C (en) | 2004-07-02 | 2013-10-08 | Genentech, Inc. | Inhibitors of iap |
CA2574040C (en) | 2004-07-15 | 2014-05-06 | Tetralogic Pharmaceuticals Corporation | Iap binding compounds |
EA019420B1 (ru) | 2004-12-20 | 2014-03-31 | Дженентех, Инк. | Пирролидиновые ингибиторы иап (ингибиторов апоптоза) |
AU2006216652A1 (en) * | 2005-02-23 | 2006-08-31 | Prexa Pharmaceuticals, Inc. | Multimediator 5-HT6 receptor antagonists, and uses related thereto |
CN103083644B (zh) | 2005-02-25 | 2014-05-28 | 泰特拉洛吉克药业公司 | Iap二聚体抑制剂 |
WO2006107964A2 (en) * | 2005-04-06 | 2006-10-12 | Novartis Ag | Processes to prepare 6-phenethyl-octahydro-pyrrolo [2 , 3-c] pyridine and related compounds |
JP4954983B2 (ja) * | 2005-05-18 | 2012-06-20 | ファーマサイエンス・インコーポレイテッド | Birドメイン結合化合物 |
US20100256046A1 (en) * | 2009-04-03 | 2010-10-07 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
US20070042428A1 (en) * | 2005-08-09 | 2007-02-22 | Stacy Springs | Treatment of proliferative disorders |
KR20080067357A (ko) | 2005-10-25 | 2008-07-18 | 에게라 쎄라퓨틱스 인코포레이티드 | Iap bir 도메인 결합 화합물 |
US8247557B2 (en) * | 2005-12-19 | 2012-08-21 | Genentech, Inc. | IAP inhibitors |
WO2007075525A2 (en) * | 2005-12-20 | 2007-07-05 | Novartis Ag | Combination of an iap-inhibitor and a taxane7 |
TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物 |
US20090233905A1 (en) * | 2006-04-05 | 2009-09-17 | Gregory Peter Burke | Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer |
RU2008143554A (ru) * | 2006-04-05 | 2010-05-10 | Новартис АГ (CH) | Комбинации терапевтических агентов для лечения рака |
US8168383B2 (en) | 2006-04-14 | 2012-05-01 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
EP3266867A1 (en) | 2006-04-14 | 2018-01-10 | Cell Signaling Technology, Inc. | Gene defects and mutant alk kinase in human solid tumors |
BRPI0711591A2 (pt) * | 2006-05-16 | 2011-11-16 | Aegera Therapeutics Inc | composto de ligação de domìnio bir da iap |
MX2008014502A (es) * | 2006-05-16 | 2008-11-27 | Aegera Therapeutics Inc | Compuestos de union a dominio de repeticion de proteinas inhibidoras de apoptosis baculovirales de las proteinas inhibidoras de apoptosis. |
WO2008014240A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
US20100144650A1 (en) * | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
US7985735B2 (en) * | 2006-07-24 | 2011-07-26 | Tetralogic Pharmaceuticals Corporation | Dimeric IAP inhibitors |
WO2008014236A1 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
JP5452223B2 (ja) | 2006-07-24 | 2014-03-26 | テトラロジック ファーマシューティカルズ コーポレーション | Iap阻害剤 |
PE20110224A1 (es) * | 2006-08-02 | 2011-04-05 | Novartis Ag | PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO |
WO2008045905A1 (en) * | 2006-10-12 | 2008-04-17 | Novartis Ag | Pyrrolydine derivatives as iap inhibitors |
RU2009118487A (ru) * | 2006-10-19 | 2010-11-27 | Новартис АГ (CH) | Органические соединения |
KR20090083412A (ko) * | 2006-11-28 | 2009-08-03 | 노파르티스 아게 | 급성 골수성 백혈병의 치료를 위한 iap 억제제의 용도 |
AU2007325280B2 (en) * | 2006-11-28 | 2011-03-10 | Dana-Farber Cancer Institute, Inc. | Combination of IAP inhibitors and FLT3 inhibitors |
CA2671607A1 (en) * | 2006-12-19 | 2008-07-03 | Genentech, Inc. | Imidazopyridine inhibitors of iap |
WO2008109057A1 (en) * | 2007-03-02 | 2008-09-12 | Dana-Farber Cancer Institute, Inc. | Organic compounds and their uses |
AU2008240153B2 (en) | 2007-04-12 | 2013-01-31 | Joyant Pharmaceuticals, Inc. | SMAC mimetic dimers and trimers useful as anti-cancer agents |
JP5368428B2 (ja) * | 2007-04-30 | 2013-12-18 | ジェネンテック, インコーポレイテッド | Iapのインヒビター |
EP2156189A1 (en) * | 2007-05-07 | 2010-02-24 | Tetralogic Pharmaceuticals Corp. | Tnf gene expression as a biomarker of sensitivity to antagonists of inhibitor of apoptosis proteins |
US20100203012A1 (en) * | 2007-05-30 | 2010-08-12 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
RU2010133548A (ru) * | 2008-01-11 | 2012-02-20 | Дженентек, Инк. (Us) | Ингибиторы iap |
MX2010007948A (es) * | 2008-01-24 | 2010-10-04 | Tetralogic Pharm Corp | Inhibidores de proteinas de apoptosis. |
US20110117081A1 (en) * | 2008-05-05 | 2011-05-19 | Aegera Therapeutics, Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
AU2009246347A1 (en) | 2008-05-16 | 2009-11-19 | Dana Farber Cancer Institute, Inc. | Immunomodulation by IAP inhibitors |
AU2009261919A1 (en) * | 2008-06-27 | 2009-12-30 | Pharmascience Inc. | Bridged secondary amines and use thereof as IAP BIR domain binding compounds |
JP2011529962A (ja) | 2008-08-02 | 2011-12-15 | ジェネンテック, インコーポレイテッド | Iapのインヒビター |
AU2009282978A1 (en) * | 2008-08-16 | 2010-02-25 | Genentech, Inc. | Azaindole inhibitors of IAP |
US8399683B2 (en) | 2008-09-17 | 2013-03-19 | Tetralogic Pharmaceuticals | IAP inhibitors |
US8841067B2 (en) | 2009-01-09 | 2014-09-23 | Dana-Farber Cancer Institute, Inc. | NOL3 is a predictor of patient outcome |
US8481495B2 (en) * | 2009-05-28 | 2013-07-09 | Tetralogic Pharmaceuticals Corporation | IAP inhibitors |
NZ596675A (en) * | 2009-05-28 | 2013-11-29 | Tetralogic Pharm Corp | Iap inhibitors |
CN101928326B (zh) * | 2009-06-24 | 2015-07-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 取代的氨酰基五元杂环烷类化合物及其用途 |
US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
WO2011016576A1 (en) | 2009-08-04 | 2011-02-10 | Takeda Pharmaceutical Company Limited | Alanine derivatives as inhibitors of apoptosis proteins |
KR20120048008A (ko) * | 2009-08-12 | 2012-05-14 | 노파르티스 아게 | 아폽토시스 단백질의 억제제의 고체 경구 제제 및 결정질 형태 |
WO2011035083A1 (en) | 2009-09-18 | 2011-03-24 | Novartis Ag | Biomarkers for iap inhibitor compounds |
EP2784076A1 (en) | 2009-10-28 | 2014-10-01 | Joyant Pharmaceuticals, Inc. | Dimeric SMAC mimetics |
NZ602368A (en) | 2010-02-12 | 2014-10-31 | Pharmascience Inc | Iap bir domain binding compounds |
UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
CA2800260C (en) * | 2010-04-19 | 2013-07-09 | Sri International | Compositions and method for the treatment of multiple myeloma |
WO2012052758A1 (en) | 2010-10-22 | 2012-04-26 | Astrazeneca Ab | Response biomarkers for iap antagonists in human cancers |
GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
JP2014528409A (ja) | 2011-09-30 | 2014-10-27 | テトラロジック ファーマシューティカルズ コーポレーション | 増殖性疾患(がん)の治療において使用するためのSMAC模倣体(ビリナパント(birinapant)) |
GB201121133D0 (en) * | 2011-12-08 | 2012-01-18 | Dow Corning | Hydrolysable silanes |
GB201121122D0 (en) | 2011-12-08 | 2012-01-18 | Dow Corning | Hydrolysable silanes and elastomer compositions containing them |
GB201121128D0 (en) | 2011-12-08 | 2012-01-18 | Dow Corning | Treatment of filler with silane |
GB201121124D0 (en) | 2011-12-08 | 2012-01-18 | Dow Corning | Hydrolysable silanes |
GB201121132D0 (en) * | 2011-12-08 | 2012-01-18 | Dow Corning | Modifying polymeric materials by amines |
US20130196927A1 (en) * | 2012-01-27 | 2013-08-01 | Christopher BENETATOS | Smac Mimetic Therapy |
RU2014148779A (ru) | 2012-05-04 | 2016-06-27 | Новартис Аг | Биомаркеры для терапии ингибитором iap |
KR20140011773A (ko) * | 2012-07-19 | 2014-01-29 | 한미약품 주식회사 | 이중 저해 활성을 갖는 헤테로고리 유도체 |
US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
MX366978B (es) | 2013-03-15 | 2019-08-01 | Novartis Ag | Conjugados de anticuerpo - farmaco. |
US20140303090A1 (en) * | 2013-04-08 | 2014-10-09 | Tetralogic Pharmaceuticals Corporation | Smac Mimetic Therapy |
EP3682873B1 (en) | 2013-06-25 | 2024-06-12 | The Walter and Eliza Hall Institute of Medical Research | Smac mimetics for use in the treatment of persistent hiv infection |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
US9278978B2 (en) | 2013-08-23 | 2016-03-08 | Boehringer Ingelheim International Gmbh | 6-Alkynyl Pyridine |
US9249151B2 (en) * | 2013-08-23 | 2016-02-02 | Boehringer Ingelheim International Gmbh | Bis-amido pyridines |
SI3083616T1 (sl) | 2013-12-20 | 2021-12-31 | Astex Therapeutics Limited | Biciklične heterociklične spojine in njihova uporaba pri zdravljenju |
CA2974651A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
WO2015187998A2 (en) | 2014-06-04 | 2015-12-10 | Sanford-Burnham Medical Research Institute | Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy |
US10786578B2 (en) | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
CN106659790A (zh) | 2014-08-12 | 2017-05-10 | 诺华股份有限公司 | 抗cdh6抗体药物缀合物 |
WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
EP3247708A4 (en) | 2015-01-20 | 2018-09-12 | Arvinas, Inc. | Compounds and methods for the targeted degradation of the androgen receptor |
US20170327469A1 (en) | 2015-01-20 | 2017-11-16 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
CN104592214A (zh) * | 2015-02-13 | 2015-05-06 | 佛山市赛维斯医药科技有限公司 | 含葡萄糖酰胺吡啶和烷氧吡嗪结构的化合物及用途 |
US20180147202A1 (en) | 2015-06-05 | 2018-05-31 | Arvinas, Inc. | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE |
EP3310813A1 (en) | 2015-06-17 | 2018-04-25 | Novartis AG | Antibody drug conjugates |
AU2016294450A1 (en) * | 2015-07-13 | 2017-12-07 | Arvinas Operations, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
WO2017030814A1 (en) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
CN105585583B (zh) * | 2016-01-20 | 2018-04-13 | 广东工业大学 | 一种非肽类凋亡抑制蛋白拮抗剂及其合成方法与应用 |
CN105566447B (zh) * | 2016-01-20 | 2019-09-20 | 广东工业大学 | 一种凋亡抑制蛋白的类肽拮抗剂及其合成方法与应用 |
CN106188098B (zh) * | 2016-07-06 | 2017-11-03 | 广东工业大学 | 一种杂化抗癌药物及其制备方法与应用 |
AU2017319135B2 (en) * | 2016-08-29 | 2021-03-18 | The Regents Of The University Of Michigan | Aminopyrimidines as ALK inhibitors |
JP6899993B2 (ja) * | 2016-10-04 | 2021-07-07 | 国立医薬品食品衛生研究所長 | 複素環化合物 |
AU2017367872B2 (en) | 2016-11-01 | 2022-03-31 | Arvinas, Inc. | Tau-protein targeting protacs and associated methods of use |
KR102173464B1 (ko) | 2016-12-01 | 2020-11-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
WO2018118598A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
WO2018119441A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Egfr proteolysis targeting chimeric molecules and associated methods of use |
US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
WO2018119448A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
MX2019008934A (es) | 2017-01-26 | 2019-11-05 | Arvinas Operations Inc | Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso,. |
JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
US11179413B2 (en) | 2017-03-06 | 2021-11-23 | Novartis Ag | Methods of treatment of cancer with reduced UBB expression |
WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
EP3630162A1 (en) | 2017-05-24 | 2020-04-08 | Novartis AG | Antibody-cytokine engrafted proteins and methods of use |
WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
PE20200303A1 (es) | 2017-05-24 | 2020-02-06 | Novartis Ag | Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer |
WO2019091492A1 (zh) * | 2017-11-13 | 2019-05-16 | 南京明德新药研发股份有限公司 | 用作iap抑制剂的smac模拟物及其用途 |
EP3710443A1 (en) | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
WO2019177902A1 (en) | 2018-03-10 | 2019-09-19 | Yale University | Modulators of btk proteolysis and methods of use |
MX2020010420A (es) | 2018-04-04 | 2020-12-11 | Arvinas Operations Inc | Moduladores de la proteólisis y métodos asociados de uso. |
ES2963694T3 (es) | 2018-07-10 | 2024-04-01 | Novartis Ag | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y su uso en el tratamiento de enfermedades dependientes de la proteína con dedos de cinc 2 de la familia ikaros (ikzf2) |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
US20200038513A1 (en) | 2018-07-26 | 2020-02-06 | Arvinas Operations, Inc. | Modulators of fak proteolysis and associated methods of use |
JP7297053B2 (ja) | 2018-08-20 | 2023-06-23 | アルビナス・オペレーションズ・インコーポレイテッド | 神経変性疾患を治療するためのe3ユビキチンリガーゼ結合活性を有するキメラ(protac)化合物を標的とし、アルファ-シヌクレインタンパク質を標的とするタンパク質分解 |
CN113164775A (zh) | 2018-09-07 | 2021-07-23 | 阿尔维纳斯运营股份有限公司 | 用于迅速加速性纤维肉瘤多肽的靶向降解的多环化合物和方法 |
EP3873532A1 (en) | 2018-10-31 | 2021-09-08 | Novartis AG | Dc-sign antibody drug conjugates |
KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
JP2022515760A (ja) | 2018-12-21 | 2022-02-22 | ノバルティス アーゲー | Pmel17に対する抗体及びその結合体 |
MX2021009763A (es) | 2019-02-15 | 2021-09-08 | Novartis Ag | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos. |
CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
EP3999182A1 (en) | 2019-07-17 | 2022-05-25 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
US20220257698A1 (en) | 2019-08-02 | 2022-08-18 | Lanthiopep B.V. | Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer |
JP2023507190A (ja) | 2019-12-20 | 2023-02-21 | ノバルティス アーゲー | 増殖性疾患を治療するための抗TGFβ抗体及びチェックポイント阻害薬の使用 |
CA3166980A1 (en) | 2020-01-20 | 2021-07-29 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
HUP2200468A1 (hu) | 2020-04-29 | 2023-03-28 | X Chem Zrt | IAP antagonisták és gyógyászati alkalmazásuk |
US20230181756A1 (en) | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
CN116096862A (zh) | 2020-06-11 | 2023-05-09 | 诺华股份有限公司 | Zbtb32抑制剂及其用途 |
WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
WO2022029573A1 (en) | 2020-08-03 | 2022-02-10 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
KR20230170738A (ko) | 2021-04-16 | 2023-12-19 | 노파르티스 아게 | 항체 약물 접합체 및 이의 제조 방법 |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
WO2024023666A1 (en) | 2022-07-26 | 2024-02-01 | Novartis Ag | Crystalline forms of an akr1c3 dependent kars inhibitor |
WO2024054591A1 (en) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
DE2714880A1 (de) * | 1977-04-02 | 1978-10-26 | Hoechst Ag | Cephemderivate und verfahren zu ihrer herstellung |
LU88769I2 (fr) | 1982-07-23 | 1996-11-05 | Zeneca Ltd | Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R)) |
JPS59141547A (ja) | 1983-02-01 | 1984-08-14 | Eisai Co Ltd | 鎮痛作用を有する新規ペプタイドおよび製法 |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
FR2575753B1 (fr) * | 1985-01-07 | 1987-02-20 | Adir | Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
DK167813B1 (da) * | 1989-12-07 | 1993-12-20 | Carlbiotech Ltd As | Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
TW225528B (hr) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
US5559209A (en) * | 1993-02-18 | 1996-09-24 | The General Hospital Corporation | Regulator regions of G proteins |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
ATE205483T1 (de) | 1995-03-30 | 2001-09-15 | Pfizer | Chinazolinderivate |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
MX9800215A (es) | 1995-07-06 | 1998-03-31 | Novartis Ag | Pirrolopirimidas y procesos para su preparacion. |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
SI0892789T2 (sl) | 1996-04-12 | 2010-03-31 | Warner Lambert Co | Ireverzibilni inhibitorji tirozin kinaz |
DE69734513T2 (de) | 1996-06-24 | 2006-07-27 | Pfizer Inc. | Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten |
NZ334821A (en) | 1996-08-30 | 2000-12-22 | Novartis Ag | Method for producing epothilones |
JP2002513445A (ja) | 1996-09-06 | 2002-05-08 | オブデュキャット、アクチボラグ | 導電材料内の構造の異方性エッチング方法 |
CA2265630A1 (en) | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
ATE408612T1 (de) | 1996-11-18 | 2008-10-15 | Biotechnolog Forschung Gmbh | Epothilone e und f |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
ATE307123T1 (de) | 1998-02-25 | 2005-11-15 | Sloan Kettering Inst Cancer | Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen |
US6472172B1 (en) * | 1998-07-31 | 2002-10-29 | Schering Aktiengesellschaft | DNA encoding a novel human inhibitor-of-apoptosis protein |
ATE459616T1 (de) | 1998-08-11 | 2010-03-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
EP1135470A2 (en) | 1998-11-20 | 2001-09-26 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
TR200200767T1 (tr) | 2000-05-23 | 2002-09-23 | Vertex Pharmaceuticals Incorporated | Kaspaz engelleyiciler ve kullanımları |
US6608026B1 (en) * | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
US20020160975A1 (en) * | 2001-02-08 | 2002-10-31 | Thomas Jefferson University | Conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO for mediating apoptosis |
AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
WO2003040172A2 (en) * | 2001-11-09 | 2003-05-15 | Aegera Therapeutics, Inc. | Methods and reagents for peptide-bir interaction screens |
EP1519918A1 (en) * | 2002-07-02 | 2005-04-06 | Novartis AG | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
ATE415413T1 (de) * | 2002-07-15 | 2008-12-15 | Univ Princeton | Iap-bindende verbindungen |
US20040171554A1 (en) * | 2003-02-07 | 2004-09-02 | Genentech, Inc. | Compositions and methods for enhancing apoptosis |
WO2005049853A2 (en) * | 2003-11-13 | 2005-06-02 | Genentech, Inc. | Compositions and methods for screening pro-apoptotic compounds |
CA2553871A1 (en) | 2004-01-16 | 2005-08-04 | The Regents Of The University Of Michigan | Smac peptidomimetics and the uses thereof |
AU2005218555B2 (en) * | 2004-03-01 | 2008-01-03 | Board Of Regents, The University Of Texas System | Dimeric small molecule potentiators of apoptosis |
AR048927A1 (es) * | 2004-04-07 | 2006-06-14 | Novartis Ag | Compuestos heterociclicos como inhibidores de proteinas de apoptosis (iap); composiciones farmaceuticas que los contienen y su uso en el tratamiento de una enfermedad proliferativa |
CA2570321C (en) | 2004-07-02 | 2013-10-08 | Genentech, Inc. | Inhibitors of iap |
EA019420B1 (ru) | 2004-12-20 | 2014-03-31 | Дженентех, Инк. | Пирролидиновые ингибиторы иап (ингибиторов апоптоза) |
PE20110224A1 (es) | 2006-08-02 | 2011-04-05 | Novartis Ag | PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO |
-
2005
- 2005-04-06 AR ARP050101365A patent/AR048927A1/es not_active Application Discontinuation
- 2005-04-06 ES ES05716547T patent/ES2394441T3/es active Active
- 2005-04-06 TW TW094110874A patent/TWI417092B/zh not_active IP Right Cessation
- 2005-04-06 KR KR1020087021449A patent/KR20080083220A/ko not_active Application Discontinuation
- 2005-04-06 CN CN2005800186137A patent/CN1964970B/zh not_active Expired - Fee Related
- 2005-04-06 SG SG200902372-2A patent/SG152225A1/en unknown
- 2005-04-06 EP EP10172398A patent/EP2253614B1/en active Active
- 2005-04-06 CA CA2560162A patent/CA2560162C/en active Active
- 2005-04-06 JP JP2007506718A patent/JP4691549B2/ja not_active Expired - Fee Related
- 2005-04-06 US US10/594,413 patent/US20080242658A1/en not_active Abandoned
- 2005-04-06 EP EP09153639A patent/EP2065368A1/en not_active Withdrawn
- 2005-04-06 KR KR1020067023240A patent/KR100892185B1/ko active IP Right Grant
- 2005-04-06 PE PE2009001297A patent/PE20110102A1/es active IP Right Grant
- 2005-04-06 MY MYPI20051543A patent/MY165401A/en unknown
- 2005-04-06 SI SI200531639T patent/SI2253614T1/sl unknown
- 2005-04-06 EP EP05716547A patent/EP1735307B1/en active Active
- 2005-04-06 US US11/099,941 patent/US7419975B2/en active Active
- 2005-04-06 RU RU2006139010/04A patent/RU2425838C2/ru active
- 2005-04-06 BR BRPI0509721-5A patent/BRPI0509721A/pt not_active Application Discontinuation
- 2005-04-06 ES ES10172398T patent/ES2396195T3/es active Active
- 2005-04-06 AU AU2005231956A patent/AU2005231956B2/en not_active Ceased
- 2005-04-06 DK DK10172398.9T patent/DK2253614T3/da active
- 2005-04-06 PE PE2005000384A patent/PE20060166A1/es active IP Right Grant
- 2005-04-06 RS RS20120557A patent/RS52545B/en unknown
- 2005-04-06 WO PCT/EP2005/003619 patent/WO2005097791A1/en active Application Filing
- 2005-04-06 PT PT101723989T patent/PT2253614E/pt unknown
- 2005-04-06 ME MEP-2012-557A patent/ME02125B/me unknown
- 2005-04-06 NZ NZ549925A patent/NZ549925A/en not_active IP Right Cessation
- 2005-04-06 PL PL10172398T patent/PL2253614T3/pl unknown
-
2006
- 2006-09-14 ZA ZA200607696A patent/ZA200607696B/en unknown
- 2006-09-14 IL IL178104A patent/IL178104A/en active IP Right Grant
- 2006-09-29 EC EC2006006893A patent/ECSP066893A/es unknown
- 2006-10-06 TN TNP2006000323A patent/TNSN06323A1/en unknown
- 2006-10-30 MA MA29422A patent/MA28630B1/fr unknown
- 2006-11-06 NO NO20065114A patent/NO20065114L/no not_active Application Discontinuation
-
2007
- 2007-06-06 HK HK07106025.9A patent/HK1100930A1/xx not_active IP Right Cessation
-
2010
- 2010-04-27 JP JP2010102494A patent/JP2010215635A/ja not_active Withdrawn
-
2011
- 2011-07-08 US US13/178,946 patent/US8207183B2/en active Active
-
2012
- 2012-04-26 US US13/456,274 patent/US8338440B2/en active Active
- 2012-12-12 HR HRP20121023TT patent/HRP20121023T1/hr unknown
- 2012-12-13 JP JP2012272668A patent/JP2013049733A/ja active Pending
- 2012-12-19 CY CY20121101238T patent/CY1113511T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20121023T1 (hr) | Inhibitori za iap | |
ES2440799T3 (es) | Métodos para tratar cáncer resistente a los fármacos | |
ES2543320T3 (es) | Acetamidas sustituídas con N-(hetero)aril,2-(hetero)arilo para uso como moduladores de señalización de Wnt | |
JP5384611B2 (ja) | 新規ヘテロ環式化合物およびそれらの使用 | |
HRP20151410T1 (hr) | Derivati pikolinamida kao inhibitori kinaze | |
CA2853454C (en) | Aminopyrimidine kinase inhibitors | |
HRP20192274T1 (hr) | Novi derivati oktahidro-pirolo[3,4−c]-pirola i njihovi analozi kao inhibitori autotaksina | |
NZ734744A (en) | Aryl-or heteroaryl-substituted benzene compounds | |
Torres et al. | Imidazoles and benzimidazoles as tubulin-modulators for anti-cancer therapy | |
JP2015523383A5 (hr) | ||
RU2017134379A (ru) | Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4 | |
CN102858770A (zh) | 双环化合物及其作为c-SRC/JAK激酶双重抑制剂的用途 | |
CA2613312A1 (en) | Phosphoramidate alkylator prodrugs | |
HRP20220886T1 (hr) | Pripravci i postupci za proizvodnju pirimidina i spojeva piridina s btk inhibicijskom aktivnošću | |
JP2015505542A5 (hr) | ||
AU2012239791A1 (en) | Protein kinase inhibitors | |
CN103848829A (zh) | 杂芳基炔烃化合物及其应用 | |
US20210395242A1 (en) | Heterocyclic compounds as ahr modulators | |
Elmorsy et al. | Synthesis, biological evaluation and molecular docking of new triphenylamine-linked pyridine, thiazole and pyrazole analogues as anticancer agents | |
HRP20231571T1 (hr) | Derivati fenil/piridil-nh-fenil/piridil za liječenje infekcija rna virusom | |
US20070213378A1 (en) | Compounds for modulating cell proliferation, compositions and methods related thereto | |
JP6826526B6 (ja) | キノキサリン化合物、それを調製する方法およびその使用 | |
BR112021012138A2 (pt) | Análogos de pentamidina e seus usos | |
Kaur et al. | Thiadiazole derivatives as protein kinase inhibitor: An insight to synthesis and structure activity relationship | |
WO2024076300A1 (en) | Compounds useful in modulation of ahr signalling |